5 terminated, 4 completed, 3 unknown, 1 active not recruiting. 10 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 3, Terminated 3, Unknown 3, Active not recruiting 1 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow immunotoxin HA22: new trials by email Literature Review of immunotoxin HA22 trials Research Report on immunotoxin HA22
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience - Hairy Cell Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2019-10-03 | 2026-06-29 |
| Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation Moxetumomab Pasudotox - Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Terminated | Center for International Blood and Marrow Transplant Research | 1 | 2015-05-01 | 2015-09-16 |
| Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma Moxetumomab Pasudotox - B-Cell Pediatric ALL | Phase 2 | Terminated | MedImmune LLC | 37 | 2014-08-01 | 2017-04-06 |
| Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) Moxetumomab Pasudotox - Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 16 | 2013-12-17 | 2023-10-13 |
| Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox - Leukemia, Hairy Cell | Phase 3 | Completed | MedImmune LLC | 80 | 2013-04-29 | 2020-04-08 |
| Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) CAT-8015 20 mcg/kg, CAT-8015 30 mcg/kg, CAT-8015 40 mcg/kg - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | MedImmune LLC | 23 | 2010-02-15 | 2018-04-09 |
| CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma CAT-8015 (Moxetumomab Pasudotox) - Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Completed | MedImmune LLC | 57 | 2008-09-01 | 2017-10-02 |
| A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL) CAT-8015 - Lymphoma | Phase 1 | Terminated | MedImmune LLC | 50 | 2007-08-01 | 2011-11-22 |
| Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy - Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Unknown | Cambridge Antibody Technology | 50 | 2007-08-01 | 2007-08-14 |
| A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia Moxetumomab Pasudotox (CAT 8015), CAT 8015 (Moxetumomab Pasudotox) - Hairy Cell Leukemia | Phase 1 | Completed | MedImmune LLC | 49 | 2007-05-10 | 2019-04-02 |
| Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy - Leukemia, Hairy Cell Leukemia | Phase 1 | Unknown | Cambridge Antibody Technology | 40 | 2007-04-01 | 2007-04-18 |
| A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia CAT-8015 5 mcg/kg, CAT-8015 10 mcg/kg, CAT-8015 20 mcg/kg - Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small | Phase 1 | Terminated | MedImmune LLC | 11 | 2007-03-07 | 2017-07-06 |
| Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease Immunotoxin therapy, CAT-8015 immunotoxin, Biological therapy - Leukemia | Phase 1 | Unknown | Cambridge Antibody Technology | 50 | 2007-03-01 | 2007-04-17 |
| An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Moxetumomab Pasudotox - Relapsed/Refractory Hairy Cell Leukemia | Approved for marketing | AstraZeneca | 2020-06-29 |
Leukemia (6) · Leukemia, Hairy Cell (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Lymphoma, Non-Hodgkin (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Recurrence (2) · Cerebral Palsy (1) · Leukemia, B-Cell (1) · Leukemia, Prolymphocytic (1) · Neoplasms (1)
MedImmune LLC (7) · Cambridge Antibody Technology (3) · AstraZeneca (1) · Center for International Blood and Marrow Transplant Research (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (13) · Poland (8) · Canada (3) · United Kingdom (3) · France (2) · Italy (2) · Spain (2) · Australia (1) · Belgium (1) · Czechia (1) · Germany (1) · Ireland (1) · Israel (1) · Netherlands (1) · Norway (1)
Alan S Wayne, MD (1) · Farhad Ravandi-Kashani, MD (1) · Mark C Lanasa, M.D.,Ph.D (1) · Nirali N Shah, MD (1) · Ramy Ibrahim, M.D. (1) · Robert J Kreitman, M.D. (1) · Robert Leechleider, M.D. (1)
PMID 18596230, PMID 22355053, PMID 28983018, PMID 29432154, PMID 29487070, PMID 31298972, PMID 32959985, PMID 33627164